entinostat has been researched along with Malignant Melanoma in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report the results of the PEMDAC phase 2 clinical trial (n = 29; NCT02697630) where the HDAC inhibitor entinostat was combined with the PD-1 inhibitor pembrolizumab in patients with metastatic uveal melanoma (UM)." | 9.41 | The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. ( All-Eriksson, C; Alsén, S; Andersson, B; Carneiro, A; Filges, S; Helgadottir, H; Jespersen, H; Karlsson, J; Levin, M; Ljuslinder, I; Nilsson, JA; Nilsson, LM; Ny, L; Olofsson Bagge, R; Sah, VR; Ståhlberg, A; Stierner, U; Ullenhag, G, 2021) |
| "The PEMDAC study is a multicenter, open label phase II study assessing the efficacy of concomitant use of the PD1 inhibitor pembrolizumab and the class I HDAC inhibitor entinostat in adult patients with metastatic uveal melanoma." | 9.30 | Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study. ( All-Eriksson, C; Andersson, B; Carneiro, A; Helgadottir, H; Jespersen, H; Levin, M; Ljuslinder, I; Nilsson, JA; Nilsson, LM; Ny, L; Olofsson Bagge, R; Stierner, U; Ullenhag, G, 2019) |
| " We report the results of the PEMDAC phase 2 clinical trial (n = 29; NCT02697630) where the HDAC inhibitor entinostat was combined with the PD-1 inhibitor pembrolizumab in patients with metastatic uveal melanoma (UM)." | 5.41 | The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. ( All-Eriksson, C; Alsén, S; Andersson, B; Carneiro, A; Filges, S; Helgadottir, H; Jespersen, H; Karlsson, J; Levin, M; Ljuslinder, I; Nilsson, JA; Nilsson, LM; Ny, L; Olofsson Bagge, R; Sah, VR; Ståhlberg, A; Stierner, U; Ullenhag, G, 2021) |
| "The PEMDAC study is a multicenter, open label phase II study assessing the efficacy of concomitant use of the PD1 inhibitor pembrolizumab and the class I HDAC inhibitor entinostat in adult patients with metastatic uveal melanoma." | 5.30 | Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study. ( All-Eriksson, C; Andersson, B; Carneiro, A; Helgadottir, H; Jespersen, H; Levin, M; Ljuslinder, I; Nilsson, JA; Nilsson, LM; Ny, L; Olofsson Bagge, R; Stierner, U; Ullenhag, G, 2019) |
| "Malignant melanoma is a highly aggressive tumor which may occur in the skin, eye, and mucous membranes." | 1.42 | The overriding of TRAIL resistance by the histone deacetylase inhibitor MS-275 involves c-myc up-regulation in cutaneous, uveal, and mucosal melanoma. ( Agliano, F; Morabito, S; Oteri, R; Teti, D; Venza, I; Venza, M; Visalli, M, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Ny, L | 2 |
| Jespersen, H | 2 |
| Karlsson, J | 1 |
| Alsén, S | 1 |
| Filges, S | 1 |
| All-Eriksson, C | 2 |
| Andersson, B | 2 |
| Carneiro, A | 2 |
| Helgadottir, H | 2 |
| Levin, M | 2 |
| Ljuslinder, I | 2 |
| Olofsson Bagge, R | 2 |
| Sah, VR | 1 |
| Stierner, U | 2 |
| Ståhlberg, A | 1 |
| Ullenhag, G | 2 |
| Nilsson, LM | 2 |
| Nilsson, JA | 2 |
| Kalin, JH | 1 |
| Wu, M | 2 |
| Gomez, AV | 1 |
| Song, Y | 1 |
| Das, J | 1 |
| Hayward, D | 1 |
| Adejola, N | 1 |
| Panova, I | 1 |
| Chung, HJ | 1 |
| Kim, E | 1 |
| Roberts, HJ | 1 |
| Roberts, JM | 1 |
| Prusevich, P | 1 |
| Jeliazkov, JR | 1 |
| Roy Burman, SS | 1 |
| Fairall, L | 1 |
| Milano, C | 1 |
| Eroglu, A | 1 |
| Proby, CM | 1 |
| Dinkova-Kostova, AT | 1 |
| Hancock, WW | 1 |
| Gray, JJ | 1 |
| Bradner, JE | 1 |
| Valente, S | 1 |
| Mai, A | 1 |
| Anders, NM | 1 |
| Rudek, MA | 1 |
| Hu, Y | 1 |
| Ryu, B | 1 |
| Schwabe, JWR | 1 |
| Mattevi, A | 1 |
| Alani, RM | 1 |
| Cole, PA | 1 |
| Venza, M | 2 |
| Visalli, M | 2 |
| Oteri, R | 1 |
| Agliano, F | 1 |
| Morabito, S | 1 |
| Teti, D | 2 |
| Venza, I | 2 |
| Beninati, C | 1 |
| Benfatto, S | 1 |
| Hauschild, A | 1 |
| Trefzer, U | 1 |
| Garbe, C | 1 |
| Kaehler, KC | 1 |
| Ugurel, S | 1 |
| Kiecker, F | 1 |
| Eigentler, T | 1 |
| Krissel, H | 1 |
| Schott, A | 1 |
| Schadendorf, D | 1 |
| Hölsken, A | 1 |
| Eyüpoglu, IY | 1 |
| Lueders, M | 1 |
| Tränkle, C | 1 |
| Dieckmann, D | 1 |
| Buslei, R | 1 |
| Hahnen, E | 1 |
| Blümcke, I | 1 |
| Siebzehnrübl, FA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter Phase II Open Label Study to Evaluate Efficacy of Concomitant Use of Pembrolizumab and Entinostat in Adult Patients With Metastatic Uveal Melanoma[NCT02697630] | Phase 2 | 29 participants (Actual) | Interventional | 2018-02-21 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for entinostat and Malignant Melanoma
| Article | Year |
|---|---|
The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma.
Topics: Antibodies, Monoclonal, Humanized; Benzamides; Humans; Melanoma; Progression-Free Survival; Pyridine | 2021 |
Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study.
Topics: Administration, Intravenous; Administration, Oral; Antibodies, Monoclonal, Humanized; Antineoplastic | 2019 |
Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Female; Histone Deacetylase Inhib | 2008 |
4 other studies available for entinostat and Malignant Melanoma
| Article | Year |
|---|---|
Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors.
Topics: Aged; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Co-Repressor | 2018 |
The overriding of TRAIL resistance by the histone deacetylase inhibitor MS-275 involves c-myc up-regulation in cutaneous, uveal, and mucosal melanoma.
Topics: Benzamides; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Drug Resistance, Neo | 2015 |
miR-92a-3p and MYCBP2 are involved in MS-275-induced and c-myc-mediated TRAIL-sensitivity in melanoma cells.
Topics: Adaptor Proteins, Signal Transducing; Aged; Antineoplastic Agents; Apoptosis; Benzamides; CASP8 and | 2016 |
Ex vivo therapy of malignant melanomas transplanted into organotypic brain slice cultures using inhibitors of histone deacetylases.
Topics: Animals; Benzamides; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Proliferati | 2006 |